More than 50% of patients infected with HCV genotype 1 fail respond to standard treatment with peginterferon plus ribavirin. Potent treatment strategies are urgently needed to improve outcomes for such patients. Novel interferons and specifically targeted antiviral therapy for HCV (STAT-C) represent promising strategies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Marcellin, P. Hepatitis B and hepatitis C in 2009. Liver Int. 29 (Suppl. 1), 1–8 (2009).
Shiffman, M. L. et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 126, 1015–1023 (2004).
Moucari, R. et al. High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy. J. Hepatol. 46, 596–604 (2007).
Poynard, T. et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 136, 1618–1628 (2009).
Moucari, R. et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 134, 416–423 (2008).
Di Bisceglie, A. M. et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N. Engl. J. Med. 359, 2429–2441 (2008).
Jensen, D. M. et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-α2b: a randomized trial. Ann. Intern. Med. 150, 528–540 (2009).
Bacon, B. R. et al. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology 49, 1838–1846 (2009).
Leevy, C. B. Consensus interferon and ribavirin in patients with chronic hepatitis C who were nonresponders to pegylated interferon alfa-2b and ribavirin. Dig. Dis. Sci. 53, 1961–1966 (2008).
Neslon, D. R. et al. Sustained virologic response with albinterferon alfa-2b/ribavirin treatment in prior interferon therapy non-responders [abstract]. Hepatology 46 (Suppl. 1), 256A (2007).
Manns, M. et al. Telaprevir in hepatitis C genotype-1-infected patients with prior non-response, viral breakthrough or relapse to peginterferon alfa-2a/b and ribavirin therapy: SVR results of the PROVE 3 study [abstract]. J. Hepatol. 50 (Suppl. 1), S379 (2009).
Schiff, E. et al. Boceprevir (B) combination therapy in null responders (NR): response dependent on Interferon responsiveness [abstract]. J. Hepatol. 48 (Suppl. 2), S46 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
P. Marcellin is a Consultant, a member of the Speaker's Bureau, and has received grant/research support from Bristol-Myers Squibb, Gilead, Novartis, Roche, Schering Plough, Tibotec and Vertex. R. Moucari declares no competing interests.
Rights and permissions
About this article
Cite this article
Moucari, R., Marcellin, P. The role of new interferons in the era of STAT-C. Nat Rev Gastroenterol Hepatol 6, 509–511 (2009). https://doi.org/10.1038/nrgastro.2009.141
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2009.141